| Autor: |
T W, Zhang, G B, Rodrigues, A V, Louie, D, Palma, A R, Dar, B, Dingle, W, Kocha, M, Sanatani, B, Yaremko, E, Yu, J, Younus, M D, Vincent |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Current oncology (Toronto, Ont.). 25(1) |
| ISSN: |
1198-0052 |
| Popis: |
We designed a phase i study of concurrent chemoradiotherapy (ccrt) with docetaxel (D) and cisplatin (C), followed by consolidation dc, for unresectable stage iii non-small cell lung cancer (nsclc).Patients with histologically proven and unresectable stage iii nsclc were eligible. During ccrt, C was given every 3 weeks (75 mg/mTwenty-six patients were enrolled, with 1 excluded following evidence of metastatic disease. Nineteen patients completed both phases of treatment. There were 7 grade 3 events during ccrt (5 esophagitis, 2 nausea), and 8 grade 3 events during consolidation (2 neutropenia, 2 leukopenia, 1 esophagitis, 2 nausea, and 1 pneumonitis). Three patients had grade 4 neutropenia. No patients died due to toxicities. The mtd of concurrent weekly D was 20 mg/mThe use of docetaxel 20 mg/m |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
